Which stock wins in a one-on-one matchup between these two genomics revolution leaders?
News & Analysis: Illumina
Questions about near-term prospects are weighing on the gene-sequencing stock.
Growth stagnated in the first half of 2019. Management says it will be temporary.
Weak preliminary Q2 results are weighing heavily on the genomic sequencing specialist.
The DNA sequencing leader moved forward in its quest to acquire Pacific Biosciences -- and Wall Street approved.
Investors were happy to hear that management is expecting a 21st straight year of sales growth in 2019.
In a year characterized by market turmoil, investors found refuge in the steady and predictable DNA sequencing king.
The genome-sequencing company beat quarterly expectations and increased its full-year guidance last month. Here's what investors need to know.
Exceptionally strong Q2 earnings results sent the gene-sequencing company's shares higher.
Strong growth in consumables revenue is keeping Wall Street happy as it awaits the continued rollout of the latest gene-sequencing machine.
The DNA-sequencing leader continued its slow and steady rise.